Home
>
US Stocks
>
Atara Biotherapeutics Inc

Atara Biotherapeutics Inc (ATRA)

$1.77

-0.15

(-7.81%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on Atara Biotherapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 51.57M → 342.0K (in $), with an average decrease of 91.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -74.57M → -74.77M (in $), with an average decrease of 0.3% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 102.8%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 107.7%

Performance

  • $1.76
    $1.87
    $1.77
    downward going graph

    0.65%

    Downside

    Day's Volatility :5.96%

    Upside

    5.35%

    downward going graph
  • $1.75
    $9.34
    $1.77
    downward going graph

    1.13%

    Downside

    52 Weeks Volatility :81.26%

    Upside

    81.05%

    downward going graph

Returns

PeriodAtara Biotherapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-56.3%
0.3%
-6.7%
6 Months
-60.93%
-8.3%
-6.2%
1 Year
-65.96%
-4.8%
-6.3%
3 Years
-83.94%
23.8%
26.9%

Highlights

Market Capitalization
173.4M
Book Value
$0.67
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.93
PEG Ratio
0.0
Wall Street Target Price
16.13
Profit Margin
0.0%
Operating Margin TTM
-454.56%
Return On Assets TTM
-46.7%
Return On Equity TTM
-148.63%
Revenue TTM
57.5M
Revenue Per Share TTM
0.56
Quarterly Revenue Growth YOY
-83.2%
Gross Profit TTM
63.6M
EBITDA
-256.0M
Diluted Eps TTM
-1.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.64
EPS Estimate Next Year
-1.9
EPS Estimate Current Quarter
-0.39
EPS Estimate Next Quarter
-0.63

Analyst Recommendation

Buy
    66%Buy
    20%Hold
    13%Sell
Based on 15 Wall street analysts offering stock ratings for Atara Biotherapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
11
Hold
3
3
3
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 811.3%

Current $1.77
Target $16.13

Technicals Summary

Sell

Neutral

Buy

Atara Biotherapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
-37.01%
-60.93%
-65.96%
-83.94%
-96.42%
Moderna, Inc.
Moderna, Inc.
-5.37%
-28.24%
-13.14%
103.02%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.12%
-3.55%
9.07%
20.95%
140.97%
Seagen, Inc.
Seagen, Inc.
-2.85%
59.4%
42.61%
21.68%
240.77%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.3%
22.83%
15.12%
110.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
NA
NA
0.0
-2.64
-1.49
-0.47
0.0
0.67
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.83
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
Buy
$173.4M
-96.42%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
578.71%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
140.97%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
240.77%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
110.67%
26.53
35.4%

Institutional Holdings

  • BlackRock Inc

    9.47%

  • Baupost Group LLC

    9.44%

  • Wasatch Advisors Inc.

    8.65%

  • State Street Corporation

    8.52%

  • JPMorgan Chase & Co

    7.76%

  • Vanguard Group Inc

    7.09%

Corporate Announcements

  • Atara Biotherapeutics Inc Earnings

    Atara Biotherapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Organization
Atara Biotherapeutics Inc
Employees
330
CEO
Dr. Pascal Touchon D.V.M.
Industry
Health Technology

Discover More

FAQs